Q-omics provides the consensus-scored C3orf22 profile across patient tissues and cancer cell-line models. C3orf22 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C3orf22 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, C3orf22 RNA expression shows 10,432 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCEC, KIRC, and LIHC as cancer lineages where C3orf22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf22 survival associations across molecular data types. C3orf22 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf22 RNA expression–survival associations across cancer types. High C3orf22 expression shows unfavorable associations in UCEC, PCPG, LUAD, DLBC and CHOL, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C3orf22 RNA expression.
This table summarizes C3orf22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C3orf22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf22 shows higher tumor expression in KIRC, KIRP, LIHC, KICH, LUAD and CHOL. The KIRC box plot shows higher C3orf22 RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with C3orf22 in patient tissues and cancer cell lines. In patient samples, C3orf22 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
